Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation

mAbs

Volumn 8, Issue 6, 2016, Pages 1098-1106

  Gong, Qian ^a   Hazen, Meredith ^a   Marshall, Brett ^a   Crowell, Susan R ^a   Ou, Qinglin ^a   Wong, Athena W ^a   Phung, Wilson ^a   Vernes, Jean Michel ^a   Meng, Y Gloria ^a   Tejada, Max ^a   Andersen, Dana ^a   Kelley, Robert F ^a  

^a GENENTECH INC   (United States)

Author keywords

ADCC; B cell depletion; CD20; IgG subclass

Indexed keywords

CD20 ANTIBODY; GLYCAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; CD20 ANTIGEN; FUCOSE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

AFUCOSYLATION; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMICAL MODIFICATION; CHO CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; GLYCOSYLATION; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; ANIMAL; B LYMPHOCYTE; BLOOD; C57BL MOUSE; CHEMISTRY; CRICETULUS; FEMALE; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE DEPLETION; MOUSE; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; B-LYMPHOCYTES; BLOOD; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FUCOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; LYMPH NODES; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SPLEEN;

EID: 84976299327     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1189049     Document Type: Article

References (35)

1. D.C.Roopenian, S.Akilesh. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; doi 10.1038/nri2155
2. R.Jefferis. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526:159-66; PMID:22465822; doi 10.1016/j.abb.2012.03.021
3. J.M.Woof, D.R.Burton. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004; 4:89-99; PMID:15040582; doi 10.1038/nri1266
4. B.Coiffier, E.Lepage, J.Briere, R.Herbrecht, H.Tilly, R.Bouabdallah, P.Morel, E.Van Den Neste, G.Salles, P.Gaulard, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42; PMID:11807147; doi 10.1056/NEJMoa011795
5. G.Cartron, L.Dacheux, G.Salles, P.Solal-Celigny, P.Bardos, P.Colombat, H.Watier. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; doi 10.1182/blood.V99.3.754
6. E.Mossner, P.Brunker, S.Moser, U.Puntener, C.Schmidt, S.Herter, R.Grau, C.Gerdes, A.Nopora, E.van Puijenbroek, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; doi 10.1182/blood-2009-06-225979
7. M.K.Leabman, Y.G.Meng, R.F.Kelley, L.E.DeForge, K.J.Cowan, S.Iyer. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs 2013; 5:896-903; PMID:24492343; doi 10.4161/mabs.26436
8. R.L.Shields, J.Lai, R.Keck, L.Y.O'Connell, K.Hong, Y.G.Meng, S.H.Weikert, L.G.Presta. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; doi 10.1074/jbc.M202069200
9. R.Niwa, A.Natsume, A.Uehara, M.Wakitani, S.Iida, K.Uchida, M.Satoh, K.Shitara. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306:151-60; PMID:16219319; doi 10.1016/j.jim.2005.08.009
10. M.J.Borrok, S.T.Jung, T.H.Kang, A.F.Monzingo, G.Georgiou. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 2012; 7:1596-602; PMID:22747430; doi 10.1021/cb300130k
11. G.Yin, E.D.Garces, J.Yang, J.Zhang, C.Tran, A.R.Steiner, C.Roos, S.Bajad, S.Hudak, K.Penta, et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. mAbs 2012; 4:217-25; PMID:22377750; doi 10.4161/mabs.4.2.19202
12. M.van der Neut Kolfschoten, J.Schuurman, M.Losen, W.K.Bleeker, P.Martinez-Martinez, E.Vermeulen, T.H.den Bleker, L.Wiegman, T.Vink, L.A.Aarden, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; doi 10.1126/science.1144603
13. J.D.Isaacs, M.G.Wing, J.D.Greenwood, B.L.Hazleman, G.Hale, H.Waldmann. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 1996; 106:427-33; PMID:8973608; doi 10.1046/j.1365-2249.1996.d01-876.x
14. M.Ivarsson, T.K.Villiger, M.Morbidelli, M.Soos. Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation. J Biotechnol 2014; 188C:88-96; PMID:25173615; doi 10.1016/j.jbiotec.2014.08.026
15. R.F.Kelley, Y.G.Meng. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol Biol 2012; 901:277-93; PMID:22723108; doi 10.1007/978-1-61779-931-0_18
16. S.Chung, V.Quarmby, X.Gao, Y.Ying, L.Lin, C.Reed, C.Fong, W.Lau, Z.J.Qiu, A.Shen, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. mAbs 2012; 4:326-40; PMID:22531441; doi 10.4161/mabs.19941
17. Y.Vugmeyster, J.Beyer, K.Howell, D.Combs, P.Fielder, J.Yang, F.Qureshi, B.Sandlund, L.Kawaguchi, W.Dummer, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005; 28:212-9; PMID:15838377; doi 10.1097/01.cji.0000155050.03916.04
18. Q.Gong, Q.Ou, S.Ye, W.P.Lee, J.Cornelius, L.Diehl, W.Y.Lin, Z.Hu, Y.Lu, Y.Chen, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174:817-26; PMID:15634903; doi 10.4049/jimmunol.174.2.817
19. C.Ferrara, F.Stuart, P.Sondermann, P.Brunker, P.Umana. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032-6; PMID:16330541; doi 10.1074/jbc.M510171200
20. P.Sondermann, R.Huber, V.Oosthuizen, U.Jacob. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; doi 10.1038/35018508
21. C.Ferrara, S.Grau, C.Jager, P.Sondermann, P.Brunker, I.Waldhauer, M.Hennig, A.Ruf, A.C.Rufer, M.Stihle, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669-74; PMID:21768335; doi 10.1073/pnas.1108455108
22. B.Scallon, S.McCarthy, J.Radewonuk, A.Cai, M.Naso, T.S.Raju, R.Capocasale. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. Int Immunopharmacol 2007; 7:761-72; PMID:17466910; doi 10.1016/j.intimp.2007.01.014
23. P.Bruhns, B.Iannascoli, P.England, D.A.Mancardi, N.Fernandez, S.Jorieux, M.Daëron. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25; PMID:19018092; doi 10.1182/blood-2008-09-179754
24. T.R.Tipton, A.Roghanian, R.J.Oldham, M.J.Carter, K.L.Cox, C.I.Mockridge, R.R.French, L.N.Dahal, P.J.Duriez, P.G.Hargreaves, et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 2015; 125:1901-9; PMID:25631769; doi 10.1182/blood-2014-07-588376
25. W.Shatz, S.Chung, B.Li, B.Marshall, M.Tejada, W.Phung, W.Sandoval, R.F.Kelley, J.M.Scheer. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs 2013; 5:872-81; PMID:23995614; doi 10.4161/mabs.26307
26. P.Bruhns. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640-9; PMID:22535666; doi 10.1182/blood-2012-01-380121
27. P.Smith, D.J.DiLillo, S.Bournazos, F.Li, J.V.Ravetch. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci U S A 2012; 109:6181-6; PMID:22474370; doi 10.1073/pnas.1203954109
28. M.B.Overdijk, S.Verploegen, A.Ortiz Buijsse, T.Vink, J.H.Leusen, W.K.Bleeker, P.W.Parren. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189:3430-8; PMID:22956577; doi 10.4049/jimmunol.1200356
29. O.Vafa, G.L.Gilliland, R.J.Brezski, B.Strake, T.Wilkinson, E.R.Lacy, B.Scallon, A.Teplyakov, T.J.Malia, W.R.Strohl. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2014; 65:114-26; PMID:23872058; doi 10.1016/j.ymeth.2013.06.035
30. A.W.Wong, T.K.Baginski, D.E.Reilly. Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnol Bioeng 2010; 106:751-63; PMID:20564613; doi 10.1002/bit.22749
31. L.Trojer, K.Gromadski, T.van de Groor, S.Buckenmaier. The mAb-glyco-chip kit - a workflow solution for rapid and fully automated characterization of N-linked glycans from monoclonal antibodies. Chromatography Today 2011; 2011:5
32. Y.Lu, J.M.Vernes, N.Chiang, Q.Ou, J.Ding, C.Adams, K.Hong, B.T.Truong, D.Ng, A.Shen, et al. Identification of IgG(1) variants with increased affinity to FcgammaRIIIa and unaltered affinity to FcgammaRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132-41; PMID:21185301; doi 10.1016/j.jim.2010.12.014
33. K.Hong, L.G.Presta, Y.Lu, A.Penn, C.Adams, A.Chuntharapai, J.Yang, W.L.Wong, Y.G.Meng. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J Immunol Methods 2004; 294:189-97; PMID:15604027; doi 10.1016/j.jim.2004.09.003
34. A.S.Miller, M.L.Tejada, H.Gazzano-Santoro. Methods for measuring antibody-dependent cell-mediated cytotoxicity in vitro. Methods Mol Biol 2014; 1134:59-65; PMID:24497354; doi 10.1007/978-1-4939-0326-9_5
35. D.Reusch, M.Haberger, B.Maier, M.Maier, R.Kloseck, B.Zimmermann, M.Hook, Z.Szabo, S.Tep, J.Wegstein, et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles–part 1: separation-based methods. mAbs 2015; 7:167-79; PMID:25524468; doi 10.4161/19420862.2014.986000